Objectives. To describe (a) the predictive value of symptoms for diagnosis of tinea capitis and (b) the rate and timing of cure with high-dose griseofulvin treatment. Methods. This prospective open-label study enrolled children aged 1 to 12 years with clinical tinea capitis. Participants with a positive dermatophyte culture received oral griseofulvin (20-25 mg/kg/day) and topical selenium sulfide shampoo for 6 weeks. Main outcome measures. The rate of symptoms of tinea capitis, and rates of mycologic and clinical cure. Results. The positive predictive values of any 1, 2, 3, or 4 symptoms for a positive culture were 88%, 82%, 78%, and 77%, respectively. The observed rates of mycologic, clinical, and complete cure were 89%, 66%, and 49%, respectively. Conclusion. In a high-risk population it is reasonable to diagnose tinea capitis using one or more cardinal symptoms. Oral griseofulvin at 20 to 25 mg/ kg/day with adjunctive shampooing for 6 weeks is moderately successful as treatment.
Ghannoum M., Isham N., Hajjeh R., et al. Tinea capitis in Cleveland: survey of elementary school students . J Am Acad Dermatol. 2002;48:189-193.
2.
Williams JV, Honig PJ, McGinley KJ, Leyden JJSemiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatrics. 1995; 96:265-267.
3.
Sharma V., Hall JC, Knapp JF, Sarai S., Galloway D., Babel DEScalp colonization by Trichophytan tonsurans in an urban pediatric clinic . Arch Dermatol. 1988;124: 1511-1513.
4.
Gupta AK, Summerbell RCIncreased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996. Med Mycol. 1998;36:55-60.
5.
Foster KW, Ghannoum MA, Elewski BEEpidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004 ;50: 748-752.
6.
Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NBAsymptomatic dermatophyte carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med. 1999;153:483-486.
7.
Abdel-Rahman SM, Simon S., Wright KJ, Ndjountche L., Gaedigk A.Tracking Trychophyton tonsurans through a large urban child care center: defining infection prevalence and transmission patterns by molecular strain typing. Pediatrics. 2006;118:2365-2373.
8.
Chen B., Friedlander S.Tinea capitis update: a continuing conflict with an old adversary. Curr Opin Pediatr. 2001; 13:331-335.
9.
Blumer J.Pharmacologic basis for the treatment of tinea capitis. Pediatr Infect Dis J. 1999;18:191-199.
10.
Fuller LC, Child FJ, Midgley G., Higgins EMClinical review: Diagnosis and management of scalp ringworm. BMJ. 2003;326:539-541.
11.
Gupta AK, Adam P., Dlova N., et al. Therapeutic options for the treatment of tinea capitis caused by Trichophytan species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol . 2001;18:433-438.
12.
Hubbard T.The predictive value of symptoms in diagnosing childhood tinea capitis. Arch Pediatr Adolesc Med. 1999;153:1150-1153.
13.
González U., Seaton T., Bergus G., Jacobson J., Martínez-Monzón C.Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev . 2007;(4): CD004685. doi:10.1002/14651858.CD004685.
14.
Elewski BE, Cáceres HW, DeLeon L., et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol . 2008;59: 41-54.
15.
Lipozencic J., Skerlev M., Orofino-Costa R., et al; Tinea Capitis Study Group.A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol . 2002; 146:816-823.
16.
Fuller LC, Smith CH, Cerio R., et al. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol . 2001;144: 321-327.
17.
American Academy of Pediatrics.2006Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove, IL: American Academy of Pediatrics; 2006:654-656.
18.
Abdel-Rahman SM, Nahata MCResponse to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother. 1997;31:406-410.
19.
Pomeranz AJ , Svapna S.Tinea capitis epidemiology, diagnosis, and management strategies. Pediatr Drugs. 2002 ; 4:779-783.
20.
Ali S., Graham TA, Forgie SEThe assessment and management of tinea capitis in children. Pediatr Emerg Care. 2007;23:662-665.
21.
Allen HB, Honig PJ, Leyden JJ, McGinley KJSelenium sulfide: adjunctive therapy for tinea capitis. Pediatrics . 1982;69:81-83.
22.
Givens TG, Murray MM, Baker RCComparison of 1% and 2.5% selenium sulfide in the treatment of tinea capitis . Arch Pediatr Adolesc Med. 1995;149:808-811.
23.
Larone D.Medically Important Fungi. Washington, DC: American Society for Microbiology Press; 2002.
Isenberg HDClinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology Press; 2004.
26.
Friedlander SF, Aly R., Krafchik B., et al. Terbanifine in the treatment of Trichophyton tinea capitis: a randomized, double blind, parallel-group duration finding study. Pediatrics. 2002;109:602-607.
27.
Gupta AK, Cooper EA, Bowen JEMeta-analysis: griseofulvin efficacy in the treatment of tinea capitis. J Drugs Dermatol. 2008;7:369-372.
